Gutierrez-Mariscal, Francisco M.
Alcalá-Diaz, Juan F.
Quintana-Navarro, Gracia M.
de la Cruz-Ares, Silvia
Torres-Peña, José D.
Cardelo, Magdalena P.
Arenas-Larriva, Antonio P.
Malagón, María M.
Romero-Cabrera, Juan L.
Ordovás, José M.
Pérez-Martínez, Pablo
Delgado-Lista, Javier
Yubero-Serrano, Elena M.
Lopez-Miranda, José http://orcid.org/0000-0002-8844-0718
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sex-specific differences in intestinal microbiota associated with cardiovascular diseases
https://doi.org/10.1186/s13293-024-00582-7
Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study
https://doi.org/10.1186/s12933-023-01933-1
Changes in quantity plant-based protein intake on type 2 diabetes remission in coronary heart disease patients: from the CORDIOPREV study
https://doi.org/10.1007/s00394-022-03080-x
Long-term effect of a dietary intervention with two-healthy dietary approaches on food intake and nutrient density in coronary patients: results from the CORDIOPREV trial
https://doi.org/10.1007/s00394-022-02854-7
Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
https://doi.org/10.1186/s12933-021-01260-3
Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.120.033214
CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics
https://doi.org/10.1016/j.ahj.2016.04.011
A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study
https://doi.org/10.1007/s00394-021-02676-z
Funding for this research was provided by:
Agencia de Innovación y Desarrollo de Andalucía (CVI-7450)
Agencia Estatal de Investigación (AGL2012/39615, AGL2015-67896-P)
Ministerio de Ciencia e Innovación (PID2019-104362RB-I00)
Instituto de Salud Carlos III (PI13/00023, PI10/01041)
Universidad de Córdoba
Article History
Received: 16 May 2022
Accepted: 21 December 2022
First Online: 4 March 2023
Declarations
:
: The authors declare that they have no current or potential conflicts of interest.
: The protocol was written in accordance with the principles of the Declaration of Helsinki. The respective Institutional Review Board (IRB) by the Human Investigation Review Committee of the Reina Sofia University Hospital (Córdoba, Spain) approved the study protocol. The trial was registered in 2009 at ClinicalTrials.gov (number NCT00924937). Recruitment took place from July 2009 to February 2012. All subjects provided written informed consent.